spacer
home > ebr > Autumn 2001
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2001
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of the articles in this issue of EBR  
view
Science and Innovation
Dr Francine Gervais, Vice-President of Research & Development at Neurochem Inc., examines Amyloid - Those Deadly Fibrils, expressing the hope that amyloid-related diseases will benefit from the successful clinical development achieved in amyloid disease-related drug programmes  
view
Cancer is one of the major killers in the developed world, accounting for over one million deaths in North America and Europe annually. As it becomes clear that new therapies with better efficacy and specificity are urgently needed, Jean-Pierre Abastado, Vice-President, Scientific Affairs at IDM considers Dendritic Cells for Cancer Immunotherapy  
view
In Putting Function First in Proteomics, Stefan Löfås, Vice President and Chief Scientific Officer at Biacore AB, describes how the last few years have seen an enormous revival in protein science and how SPR technology provides not only a means of isolating novel proteins, but also of uncovering their functional properties  
view
bullet
REVIEWS AND PREVIEWS
A New Age for Biotechnology - 18th to 19th June 2001, London  
view
Backström & Co Ltd. consider Biotechnology and Patents From the Finnish Point of View  
view
Accentus - Meeting Your Contract Manufacturing Needs  
view
bullet
INTERVIEW
In an interview with our Editor, Dr Helen Abbott, Taylor Crouch, CEO of Variagenics, Inc., considers the dawning of a brave new world as Personalised Medicine Draws Nearer  
view
bullet
MARKETPLACE
In Medicon Valley - The Scandinavian Hotspot, Ulf Åberg, Managing Director of Region Skåne, looks at how the area, with 54,000 people working within the medical industry, is rapidly emerging as one of Europe's dynamic centres of biotechnology and pharmaceutical development  
view
As New York's State Government takes an aggressive approach to enhance bio-basedindustry growth in the region, Jeffrey Saelens, Manager of the Technology Information Unit; Keith Servis, Director for Programs; and Russell W Bessette, Executive Directorof NYSTAR, describe New York - The Biotechnology State: A New Renaissance  
view
bullet
BUSINESS STRATEGY
The market capitalisation of leading generics companies has increased during the last decade, and numerous changes in industry structure are expected to trigger continued growth. In The Emergence of Biogenerics, Klaus Maleck, Chief Financial Officer, and Federico Pollano, Head of Business Development at BioGeneriX AG, explain why investors have big hopes for the generics industry  
view
Mario Johnson, Pharmaceutical Industry Manager for DHL International (UK) Ltd, highlights the fundamental changes that are reshaping the industry and addresses some of the challenges that it must face in Distribution of Temperature-Sensitive Products - When Time is More than Just Money  
view
In Prion Safety of Biopharmaceuticals and Blood-Related Products, Melanie Dippel, Corporate Communications Manager at NewLab BioQuality AG, provides an overview of the subject of prion safety, the actions of international regulatory authorities, and the consequences for medicinal product manufacturers  
view
bullet
LICENSING AND REGULATORY
The compilation, dissemination and use of databases containing human genetic information raise obvious data protection and privacy concerns. In a bid to identify ways of overcoming legislative obstacles, Myles Jelf, Associate, Bristows, poses the question, Data Protection - Can Anonymising Data Protect You?  
view
bullet
RESEARCH AND DEVELOPMENT
In a world where chemistry is the key to a post-genomic future, forming the link between biological targets and drug development, Candace O'Connor, a Freelance Medical Journalist, explores Chemistry as Business in the New Chemo-Genomic Era  
view
Dr Hermann Allgaier, Managing Director of Operations at LSMW GmbH, looks at Innovative Facility Concepts for Biopharmaceutical Multipurpose Pilot and Production Plants, explaining how varying manufacturing requirements strongly influence the design concept for pharmaceutical facilities  
view
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Delivering peace of mind

Help is on the horizon for patients juggling complicated treatment regimens for chronic diseases such as rheumatoid arthritis (RA). A novel approach to drug delivery from technology and product design firm Cambridge Design Partnership (CDP) paving the way for a new generation of treatment that is easier for patients and cost effective for healthcare providers.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

Industry Events

INTERPHEX 2018

17-18 April 2018, Javits Center, New York, USA

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA).
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement